# MOTS-c peptide Research: Mechanism, Key Studies, and Recent Data > MOTS-c peptide research: the folate-cycle/AMPK mechanism, mitochondrial-to-nuclear retrograde signaling, the CK2 target, and the 2024-2025 cardiometabolic studies. Cited and depth-graded. From the 2015 founding paper to the 2025 diabetic-heart work — the mechanism and the evidence, each finding graded by how deep its certainty runs. ## Before the details This page covers how the MOTS-c peptide works and what the studies measured. The core idea is simple: MOTS-c jams one metabolic pathway (the folate cycle), which trips a fuel sensor called AMPK, which in turn improves how muscle handles sugar. A second idea is stranger and more interesting — under stress, this mitochondrial peptide travels up to the cell nucleus and changes gene activity. Almost all of the evidence is from mice and cultured cells. We label every animal or cell result as preclinical so the distinction from human data is never lost. ## Mechanism: folate-cycle inhibition to AMPK MOTS-c's central action is inhibition of the folate cycle and de novo purine biosynthesis — the one-carbon reactions that supply building blocks for new DNA and RNA [1]. Blocking that cycle causes AICAR (5-aminoimidazole-4-carboxamide ribonucleotide, a purine-synthesis intermediate) to accumulate, and AICAR activates AMPK (AMP-activated protein kinase, the master cellular energy sensor) [1]. Activated AMPK shifts metabolism toward energy production and glucose uptake, which is the mechanistic root of MOTS-c's metabolic effects, identified primarily in skeletal muscle [1]. A 2024 study in *iScience* added a direct molecular target: MOTS-c binds and activates casein kinase 2 (CK2) in cell-free systems, and tissue-specific CK2 modulation — activation in muscle, suppression in fat — underlies its effects on muscle glucose uptake and atrophy prevention [10]. This is the first identified direct binding partner for the peptide. ## MOTS-c mechanism of action: retrograde signaling to the nucleus Under metabolic stress, MOTS-c translocates from the mitochondrion to the nucleus and regulates nuclear gene expression in an AMPK-dependent manner [3]. This was the first demonstrated retrograde signaling — communication from the mitochondrion back to the nucleus — by a mitochondrial-encoded peptide. In human and mouse cells exposed to glucose restriction (0.5 g/L), serum deprivation (1% FBS), or oxidative stress (tBHP 100 uM), MOTS-c drove AMPK-dependent regulation of antioxidant-response-element (ARE) genes through interaction with NRF2 (nuclear factor erythroid 2-related factor 2, the transcription factor that governs the cell's antioxidant and detoxification genes) [3]. The pathway list is consistent across the literature: folate-cycle/one-carbon inhibition, AICAR-driven AMPK activation, mitochondrial-to-nuclear retrograde signaling, NRF2/ARE gene regulation, direct CK2 binding, and — in tissue-specific contexts — RANKL/osteoclast and TGF-beta/SMAD modulation in bone and TRIM72 (MG53) trafficking for membrane repair [4][10]. ## The founding metabolic studies The 2015 *Cell Metabolism* paper identified MOTS-c, established its folate-cycle/AMPK mechanism, and showed that treatment prevented diet-induced obesity and insulin resistance in C57BL/6 mice, using ~0.5 mg/kg/day intraperitoneally (IP) for chronic dosing (~8 weeks) and 5 mg/kg/day IP for acute work (7 days) [1]. It named skeletal muscle as the primary target and AMPK as the downstream effector [1]. The exercise-mimetic role came from a 2021 *Nature Communications* study: exercise induced endogenous MOTS-c in muscle and circulation, and exogenous MOTS-c (15 mg/kg/day IP, or 15 mg/kg IP three times weekly) significantly improved physical capacity across young, middle-aged, and old mice, with the treadmill-capacity effect in aged animals reaching P=0.000002 [2]. Two foundational reviews place MOTS-c among mitochondrially derived peptides as regulators of systemic metabolism and aging [8][9]. ## Recent data: 2024-2025 The recent literature extends MOTS-c into cardiometabolic and stress-injury models, and into the strongest human-association cohort so far. A 2024 *Blood Purification* multicenter cohort of 94 chronic hemodialysis patients found circulating MOTS-c independently associated with all-cause mortality and non-fatal cardiovascular events (Cox HR 1.004, p=0.05), improving model discrimination from ROC AUC 0.727 to 0.743 [11]. A 2025 *Frontiers in Physiology* study in a rat type-2-diabetes model (high-fat diet plus low-dose streptozotocin) reported that MOTS-c increased OXPHOS respiration in cardiac mitochondria and was associated with reduced fasting glucose and left-ventricular hypertrophy [12]. A 2024 *Diabetes Research and Clinical Practice* study showed eight weeks of high- and moderate-intensity interval exercise altered mitochondrial MOTS-c and metabolic markers in a diabetic sand-rat model in an intensity-dependent manner [13]. Beyond the cardiometabolic lens, MOTS-c promoted glycolysis via an AMPK-HIF-1alpha-PFKFB3 pathway to ameliorate cardiopulmonary-bypass-induced lung injury in a rodent model [14], and attenuated mitochondrial dysfunction, pyroptosis, and cartilage degradation in osteoarthritis models through an Nrf2-dependent mechanism [15]. ## How to read this evidence The shape of the MOTS-c record is distinctive: a thin lit band of human signal near the surface (the 2024 hemodialysis cohort [11]; the pediatric biomarker associations [5][6]) over a broad preclinical mid-water (the founding metabolic work [1], the exercise-mimetic capacity study [2], the diabetic-heart respiration study [12], the CK2 target study [10]) descending into the abyss of honest gaps. No completed human efficacy trial exists. Several findings — including some human biomarker studies and newer mechanistic results — are small, single-lab, or await independent replication [4]. The cardiometabolic detail lives on [MOTS-c cardiometabolic research](/cardiometabolic-research); the dose context lives on [MOTS-c dosage in the research literature](/dosage). --- A depth-gauged reading of the MOTS-c mitochondrial-peptide record — the human signal logged near the surface, the preclinical findings in the mid-water, and the honest gaps left visible in the abyss, with no clinic behind the gauge and nothing here stocked, priced, or sold.